These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24608234)

  • 1. Disease control implications of India's changing multi-drug resistant tuberculosis epidemic.
    Suen SC; Bendavid E; Goldhaber-Fiebert JD
    PLoS One; 2014; 9(3):e89822. PubMed ID: 24608234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.
    Sachdeva KS; Raizada N; Gupta RS; Nair SA; Denkinger C; Paramasivan CN; Kulsange S; Thakur R; Dewan P; Boehme C; Arinaminpathy N
    PLoS One; 2015; 10(7):e0131438. PubMed ID: 26132584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
    Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
    Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistant tuberculosis: trends and control.
    Prasad R; Gupta N; Singh M
    Indian J Chest Dis Allied Sci; 2014; 56(4):237-46. PubMed ID: 25962197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India.
    Sethi S; Mewara A; Dhatwalia SK; Singh H; Yadav R; Singh K; Gupta D; Wanchu A; Sharma M
    BMC Infect Dis; 2013 Mar; 13():137. PubMed ID: 23497169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding how geographic, demographic and treatment history impact health outcomes of patients with multi-drug-resistant tuberculosis in Pakistan, 2014-2017.
    Iqbal F; Defer MK; Latif A; Hadi H
    Epidemiol Infect; 2020 Sep; 148():e253. PubMed ID: 32993828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of patient treatment pathways among multidrug-resistant and drug-sensitive TB cases in Delhi, India: A cross-sectional study.
    Sharma N; Bhatnagar A; Basu S; Khanna A; Chopra KK; Banerjee B; Sharma N; Chandra S; Khanna V; Arora R; Babbar N
    Indian J Tuberc; 2020 Oct; 67(4):502-508. PubMed ID: 33077051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The making of a public health problem: multi-drug resistant tuberculosis in India.
    Engel NC
    Health Policy Plan; 2013 Jul; 28(4):375-85. PubMed ID: 22865835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic mutations associated with rifampicin and isoniazid resistance in MDR-TB patients in North-West India.
    Kumar P; Kumar P; Balooni V; Singh S
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):434-9. PubMed ID: 25859999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.
    Kendall EA; Azman AS; Cobelens FG; Dowdy DW
    PLoS One; 2017; 12(3):e0172748. PubMed ID: 28273116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Multi-Drug Resistant
    Ali S; Khan MT; Khan AS; Mohammad N; Khan MM; Ahmad S; Noor S; Jabbar A; Daire C; Hassan F
    Pol J Microbiol; 2020; 69(2):1-5. PubMed ID: 32249555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing patterns and trends of multidrug-resistant tuberculosis at referral centre in Northern India: a 4-year experience.
    Maurya AK; Singh AK; Kumar M; Umrao J; Kant S; Nag VL; Kushwaha RA; Dhole TN
    Indian J Med Microbiol; 2013; 31(1):40-6. PubMed ID: 23508428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
    Chang KC; Yew WW
    Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead.
    van Maaren PJ
    Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and patterns of drug resistant pulmonary tuberculosis in India-A systematic review and meta-analysis.
    Lohiya A; Suliankatchi Abdulkader R; Rath RS; Jacob O; Chinnakali P; Goel AD; Agrawal S
    J Glob Antimicrob Resist; 2020 Sep; 22():308-316. PubMed ID: 32247079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
    Muniyandi M; Ramachandran R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission of multi-drug resistant tuberculosis in Mongolia is driven by Beijing strains of Mycobacterium tuberculosis resistant to all first-line drugs.
    Gurjav U; Erkhembayar B; Burneebaatar B; Narmandakh E; Tumenbayar O; Hill-Cawthorne GA; Marais BJ; Sintchenko V
    Tuberculosis (Edinb); 2016 Dec; 101():49-53. PubMed ID: 27865397
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.